This document discusses renal tubular acidosis (RTA). It describes the different types of RTA (proximal, distal, and hyperkalemic) and explains their pathophysiology. For each type it covers the mechanisms of impaired acidification, clinical manifestations like acidosis and electrolyte abnormalities, and treatments involving bicarbonate replacement. Key points are that proximal RTA involves impaired bicarbonate reabsorption, distal RTA impaired hydrogen ion secretion, and hyperkalemic RTA impaired aldosterone effects. Diagnosis involves assessing the nature of the metabolic acidosis through blood and urine tests.
metabolic acidosis develops because of defects in the ability of the renal tubules to perform the normal functions required to maintain acid-base balance.
metabolic acidosis develops because of defects in the ability of the renal tubules to perform the normal functions required to maintain acid-base balance.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
India Diagnostic Labs Market: Dynamics, Key Players, and Industry Projections...Kumar Satyam
According to the TechSci Research report titled “India Diagnostic Labs Market Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2019-2029,” the India Diagnostic Labs Market was valued at USD 16,471.21 million in 2023 and is projected to grow at an impressive compound annual growth rate (CAGR) of 11.55% through 2029. This significant growth can be attributed to various factors, including collaborations and partnerships among leading companies, the expansion of diagnostic chains, and increasing accessibility to diagnostic services across the country. This comprehensive report delves into the market dynamics, recent trends, drivers, competitive landscape, and benefits of the research report, providing a detailed analysis of the India Diagnostic Labs Market.
Collaborations and Partnerships
Collaborations and partnerships among leading companies play a pivotal role in driving the growth of the India Diagnostic Labs Market. These strategic alliances allow companies to merge their expertise, strengthen their market positions, and offer innovative solutions. By combining resources, companies can enhance their research and development capabilities, expand their product portfolios, and improve their distribution networks. These collaborations also facilitate the sharing of technological advancements and best practices, contributing to the overall growth of the market.
Expansion of Diagnostic Chains
The expansion of diagnostic chains is a driving force behind the growing demand for diagnostic lab services. Diagnostic chains often establish multiple laboratories and diagnostic centers in various cities and regions, including urban and rural areas. This expanded network makes diagnostic services more accessible to a larger portion of the population, addressing healthcare disparities and reaching underserved populations. The presence of diagnostic chain facilities in multiple locations within a city or region provides convenience for patients, reducing travel time and effort. A broader network of labs often leads to reduced waiting times for appointments and sample collection, ensuring that patients receive timely and efficient diagnostic services.
Rising Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases is a significant driver for the demand for diagnostic lab services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer require regular monitoring and diagnostic testing for effective management. The rise in chronic diseases necessitates the use of advanced diagnostic tools and technologies, driving the growth of the diagnostic labs market. Additionally, early diagnosis and timely intervention are crucial for managing chronic diseases, further boosting the demand for diagnostic lab services.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
2. TUBULAR FUNCTION
• 2/3 of glomerular ultra filtrate
is reabsorbed from the PT
• 60% of Na ia absorbed in the
PT & 25% in the ALH &15%
in the DT.
• All filterd K is reabsorbed in
PT & excretion occur in DT
and collecting ducts.
• H excretion occur in early
parts of PT and also DT.
• Ca reabsorption occur in
parallel with Na reabsorption
• Majority of PH is reabsorbed
in the PT.
• The process of K and H ion
excretion and Na
reabsorption iall stimulated
by aldosteron.
• 85% of bicarbonate is
reabsorbed in PT and the
remaining 15% reabsorbed in
the DT
3.
4. Acidosis & anion gap
< 12 = normal or absence of anion gap
RTA
carbonic anhydrase inhibitor ,
Ureterosigmoidostomy
pancreatic fistula
diarhea
5. Acidosis & anion gap
>16 =increased anion gap
• lactic acidosis
• DKA
• inborn errors of metabolism
• Uremia
• poisoning with (salicylate,methanol,ethanol)}
6. Normal Urinary Acidification
• Urinary acidification involves two processes:
• Bicarbonate reabsorption and
• Hydrogen ion excretion .
7. Normal Urinary Acidification
In infants, bicarbonate reabsorption is less efficient,
and renal bicarbonate excretion may occur at serum
concentrations less than 22 mmol/L.
The hydrogen ion in the tubular lumen binds with
bicarbonate and, under the influence of carbonic
anhydrase, is converted to carbon dioxide and water.
8. Normal Urinary Acidification
Secretion of the daily acid load (approximately 1
mEq/kg/24 hr produced during normal cellular
processes) is accomplished by hydrogen ion secretion
Approximately 85% of the filtered bicarbonate is
reabsorbed in the proximal tubule .
The remaining 15% of bicarbonate is reabsorbed
distally
9. DEFINITION
• metabolic acidosis due to a defect at the
level of the renal tubule.
• non-anion gap or hyperchloremic
metabolic acidosis ------------ from loss of
bicarbonate
inability to reabsorb HCO3 or
retention of hydrogen ion (inability to excrete).
15. TYPES OF RTAs
• Distal ------------------loss of hydrogen ion
secretion into urine
• Proximal ---------------- loss of bicarbonate
reabsorption
• Hypoaldosteronism or hyperkalemic (Type
IV): ----------- distal tubule resistance to
aldosterone ----------loss of potassium
excretion--------hyperkalemia ------------
suppression of ammonia excretion.
17. Proximal (Type II) Renal
Tubular Acidosis
• Pathogenesis
Impaired proximal tubule bicarbonate reabsorption.
Isolated forms of inherited or acquired proximal occur,
Autosomal dominant forms,
As well as an autosomal recessive form associated with ocular
abnormalities, have been reported.
More typically, proximal rta occurs as a component of global proximal
tubule dysfunction or fanconi syndrome. Both autosomal dominant
and autosomal recessive forms of primary fanconi syndrome occur.
In addition, secondary fanconi syndrome may occur as a component
of one of several inherited renal tubular disorders or in acquired
disease states.
21. Clinical Manifestations
• Patients with isolated, sporadic, or inherited
proximal RTA commonly present with growth
failure in the first year of life.
• Additional symptoms may include polyuria,
dehydration (due to sodium losses), anorexia,
vomiting, constipation, and hypotonia.
22. Clinical Manifestations
Patients with PRIMARY FANCONI SYNDROME will have
additional symptoms secondary to phosphate wasting such as
rickets.
Those with systemic diseases will present with additional signs
and symptoms specific to their underlying disease.
A non-anion gap metabolic acidosis will be present.
Urinalysis in patients with isolated proximal RTA is generally
unremarkable.
The urine pH is acidic (<5.5), because distal acidification
mechanisms are intact in these patients.
23. Distal (Type I) Renal Tubular
Acidosis
Pathogenesis
Impaired distal urinary acidification (hydrogen ion secretion).
Damaged or impaired functioning of one or more transporters or proteins
involved in the acidification process, including the h+/atpase, the hco3-/cl-
anion exchangers or the components of the aldosterone pathway.
Because of impaired hydrogen ion excretion, urine ph cannot be reduced
below 5.5, despite the presence of severe metabolic acidosis.
Loss of sodium bicarbonate results in hyperchloremia and hypokalemia.
24. Pathogenesis
Hypercalciuria is usually present and may lead to
nephrocalcinosis or nephrolithiasis.
Chronic metabolic acidosis also impairs urinary citrate excretion.
Hypocitraturia further increases the risk of calcium deposition in
the tubules.
Bone disease is common, resulting from mobilization of organic
components from bone to serve as buffers to chronic acidosis.
Both primary sporadic or inherited forms occur. As with
proximal RTA, distal RTA can also occur as a complication of either
inherited or acquired diseases of the distal tubules.
25. Toluene induced RTA 1
Present in glue
Inhibits proton secretion
Produceshipuuirc and benxzopic acid
Buffered by bicarbonate, resulting in acidosis.
26.
27. Clinical Manifestations
Non-anion gap metabolic acidosis and growth
failure.
However, distinguishing features of distal RTA
include nephrocalcinosis and hypercalciuria.
The phosphate and massive bicarbonate
wasting characteristic of proximal RTA is
generally absent.
28. Hyperkalemic (Type IV) Renal
Tubular Acidosis
• Pathogenesis:
impaired aldosterone production (hypoaldosteronism) OR
impaired renal responsiveness to aldosterone ("pseudo" hypoaldosteronism).
Because aldosterone has a direct effect on the H+ ATPase responsible for hydrogen
secretion, acidosis results.
In addition, aldosterone is a potent stimulant for potassium secretion in the collecting
tubule.
Loss of aldosterone effect results in hyperkalemia.
29. Pathogenesis:
This further affects acid-base status by inhibiting ammoniagenesis
and, thus, hydrogen ion excretion.
Aldosterone deficiency typically occurs as a result of adrenal gland
disorders such as Addison disease or congenital adrenal hyperplasia
(CAH).
30. Pathogenesis:
In children, aldosterone unresponsiveness is a more common cause
of type IV RTA.
This may occur transiently, during an episode of acute
pyelonephritis or acute urinary obstruction, or chronically, particularly
in infants and children with a history of obstructive uropathy.
The latter patients may have significant hyperkalemia, even in
instances when renal function is normal or only mildly impaired.
Rare examples of inherited forms of type IV RTA have been
identified.
31.
32. Clinical Manifestations.
Patients with type IV RTA, like those with types I and II
RTA, may present with growth failure in the first few
years of life.
Polyuria and dehydration (from salt wasting) are
common. Rarely, patients (especially those with
pseudohypoaldosteronism type 1) will present with life-
threatening hyperkalemia.
33. Clinical Manifestations.
Patients with obstructive uropathies may present
acutely with signs and symptoms of pyelonephritis,
such as fever, vomiting, and foul-smelling urine.
Laboratory tests reveal a hyperkalemic non-anion gap
metabolic acidosis.
Urine may be alkaline or acidic.
Elevated urine sodium levels with inappropriately low
urine potassium levels reflect the absence of
aldosterone effect.
34. Diagnosis of RTA
• confirm the presence of and nature of the metabolic
acidosis.
• assess renal function.
• rule out other causes of metabolic acidosis, such as
diarrhea ( which is extremely common) .
• identify electrolyte abnormalities (K,Na,Cl)
• blood urea nitrogen, calcium, phosphorus, and creatinine
and pH
blood should be obtained by
venous puncture. Traumatic blood draws (such as heel stick specimens) or
prolonged specimen transport time can lead to falsely low bicarbonate
levels, often in association with an elevated serum potassium value.
35. Diagnosis of RTA
True hyperkalemic acidosis is consistent with type IV RTA, whereas
the finding of normal or low potassium suggests type I or II.
36. Urine pH
Urine pH may help distinguish distal from proximal causes.
A urine pH of less than 5.5in the presence of acidosis
suggests proximal RTA,
whereas patients with distal RTA typically have a urine pH
of more than 5.5
37.
38.
39. URINALYSIS
A urinalysis should also be obtained to determine the
presence of glycosuria, proteinuria, or hematuria
suggesting the possibility of more global tubular
damage or dysfunction .
40.
41.
42. Urine Calcium
Random or 24-hr urine calcium and
creatinine measurements will identify
hypercalciuria .
43. Renal ultrasound
A renal ultrasound should be obtained to identify
underlying structural abnormalities such as
obstructive uropathies as well as to determine
the presence of nephrocalcinosis.
44. Ultrasound examination of a child with distal renal
tubular acidosis demonstrating medullary
nephrocalcinosis
45. Treatment:
• Patients with proximal RTA often require large quantities
of bicarbonate, up to 20 mEq/kg/24 hr in the form of
sodium bicarbonate or sodium citrate solution (Bicitra or
Shohl's solution). Also we have( polycitra solution) which
same as bictra with adding of potassium citrate.
• The base requirement for distal RTAs is generally in the
range of 2-4 mEq/kg/24 hr, although patient
requirements may vary .
• Patients with distal RTA should be monitored for the
development of hypercalciuria. Those with symptomatic
hypercalciuria (e.g., recurrent episodes of gross
hematuria), nephrocalcinosis, or nephrolithiasis may
require thiazide diuretics to decrease urine calcium
excretion.
46. Treatment of RTA cont.
• Patients with type IV RTA may require chronic treatment
for hyperkalemia with sodium-potassium exchange resin
(Kayexalate).
• The mainstay of therapy in all forms of RTA is
bicarbonate replacement .
47. Save the bones:
Rickets may be present in primary renal tubular acidosis (RTA),
particularly in type II or proximal RTA.
Administration of sufficient bicarbonate to reverse acidosis stops bone
dissolution and the hypercalciuria that is common in distal RTA.
Proximal RTA is treated with both bicarbonate and oral phosphate
supplements to heal bone disease.
Doses of phosphate similar to those used in familial
hypophosphatemia or Fanconi syndrome should be used.
Vitamin D is needed to offset the secondary hyperparathyroidism that
complicates oral phosphate therapy